Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study

Journal of B.U.ON.

Volumn 8, Issue 2, 2003, Pages 127-132

  Aravantinos, Gerasimos ^a   Linardou, H ^a   Makridaki, D ^a   Laiou, E ^a   Zafiropoulos, A ^a   Janninis, J ^a   Sofos, G ^b   Gikas, D ^b   Samantas, E ^a   Markantoni Kyroudi, S ^c  

^a AGII ANARGIRI CANCER HOSPITAL   (Greece)

^b General Hospital of Chalkis   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anaemia; Erythropoietin; Platinum chemotherapy; Randomised study

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETOPOSIDE; HEMOGLOBIN; IRON; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE COUNT; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEALTH CARE COST; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MALE; OVARY CANCER; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; STATISTICAL SIGNIFICANCE; STOMACH CANCER; TREATMENT INDICATION;

EID: 0345307679     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: Pathophysiology and treatment. Cancer Treat Rev 2000; 26: 303-311.
2. Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 1998; 15: S19-S28.
3. Bray GL, Reaman GH. Erythropoietin deficiency: A complication of cisplatin therapy and its treatment with recombinant human erythropoietin. Am J Pediatr Hematol Oncol 1991; 13: 426-430.
4. Koeller JM. Clinical guidelines for the treatment of cancer-related anaemia. Pharmacotherapy 1998; 18: 156-169.
5. Krantz SB. Erythropoietin. Blood 1991; 77: 419-434.
6. Adamson JW. Epoetin alfa: Into the new millenium. Semin Oncol 1998; 25: 76-79.
7. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A: S2-S8.
8. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anaemia: A randomised, double-blind trial with placebo. J Clin Oncol 1994; 12: 1058-1062.
9. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-1234.
10. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumour type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16: 3412-3425.
11. Crawford J, Blackwell S. Erythropoietin and the management of anemia in patients with lung cancer. Cancer Control 1998; 5 (Suppl 2): 26S-32S.
12. Dunphy FR, Dunleavy TL, Harrison BR, et al. Erythropoietin reduces anaemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997; 79: 1623-1628.
13. Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JJ, Hilton JG, Boyd JH. Erythropoietin reduces anaemia and transfusions: A randomised trial with or without erythropoietin during chemotherapy. Cancer 1999; 86: 1362-1367.
14. Thatcher N, De Campos ES, Bell DR et al. Epoetin alfa prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999; 80: 396-402.
15. Adamson JW, Ludwig H. Predicting the haematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anaemia of cancer. Oncology 1999; 56: 46-53.
16. Beguin Y. Prediction of response to optimise outcome of treatment with erythropoietin. Semin Oncol 1998; 25: S27-S34.
17. Ziras N, Rozakou AJ, Skoura S et al. Soluble transferring receptor: An early predicting index of response to epoetin alfa treatment for the prophylaxis of chemotherapy-induced anemia in patients with solid tumors. J BUON 2001; 6: 67-73.
18. Groopman JE, Itri LM. Chemotherapy-induced anaemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634.
19. Glaspy J, Cavill I. Role of iron in optimising responses in anaemic cancer patients to erythropoietin. Oncology 1999; 13: 461-473.
20. Oberhoff C, Neri B, Amadori D et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors. A randomized, controlled study. Ann Oncol 1998; 9: 255-260.
21. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomised, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
22. Seidenfeld J, Piper M, Flamm C et al. Epoetin treatment of anaemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93: 1204-1214.